Dasatinib in Imatinib-Resistant Philadelphia Chromosome–Positive Leukemias

20061,764 citationsJournal Articlebronze Open Access

Authors

Moshe Talpaz · TherapeuticsMD (United States)

Neil P. Shah · University of California, Los Angeles

Hagop M. Kantarjian · The University of Texas MD Anderson Cancer Center

Nicholas J. Donato · TherapeuticsMD (United States)

John Nicoll · University of California, Los Angeles

Ron Paquette · University of California, Los Angeles

Jörge E. Cortes

Abstract

Dasatinib induces hematologic and cytogenetic responses in patients with CML or Ph-positive ALL who cannot tolerate or are resistant to imatinib. (ClinicalTrials.gov number, NCT00064233 [ClinicalTrials.gov].).

Topics & Keywords

Chronic Myeloid Leukemia Treatments Eosinophilic Disorders and Syndromes Chronic Lymphocytic Leukemia Research

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 354, Issue 24, pp. 2531-2541

DOI: 10.1056/nejmoa055229

Field-Weighted Citation Impact: 86.83